JP7181185B2 - アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 - Google Patents

アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 Download PDF

Info

Publication number
JP7181185B2
JP7181185B2 JP2019514754A JP2019514754A JP7181185B2 JP 7181185 B2 JP7181185 B2 JP 7181185B2 JP 2019514754 A JP2019514754 A JP 2019514754A JP 2019514754 A JP2019514754 A JP 2019514754A JP 7181185 B2 JP7181185 B2 JP 7181185B2
Authority
JP
Japan
Prior art keywords
formulation
acetaminophen
sulfoalkyl ether
ether cyclodextrin
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532927A5 (enExample
JP2019532927A (ja
Inventor
ラエフスキー，ロジャー
ディー． ピプキン，ジェイムズ
エル． モシャー，ジェロルド
Original Assignee
サイデックス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイデックス・ファーマシューティカルズ・インコーポレイテッド filed Critical サイデックス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2019532927A publication Critical patent/JP2019532927A/ja
Publication of JP2019532927A5 publication Critical patent/JP2019532927A5/ja
Priority to JP2022125300A priority Critical patent/JP2022140780A/ja
Application granted granted Critical
Publication of JP7181185B2 publication Critical patent/JP7181185B2/ja
Priority to JP2024028183A priority patent/JP2024051102A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2019514754A 2016-09-16 2017-09-15 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 Active JP7181185B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022125300A JP2022140780A (ja) 2016-09-16 2022-08-05 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2024028183A JP2024051102A (ja) 2016-09-16 2024-02-28 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395794P 2016-09-16 2016-09-16
US62/395,794 2016-09-16
PCT/US2017/051919 WO2018053358A1 (en) 2016-09-16 2017-09-15 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022125300A Division JP2022140780A (ja) 2016-09-16 2022-08-05 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤

Publications (3)

Publication Number Publication Date
JP2019532927A JP2019532927A (ja) 2019-11-14
JP2019532927A5 JP2019532927A5 (enExample) 2020-11-05
JP7181185B2 true JP7181185B2 (ja) 2022-11-30

Family

ID=61619250

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019514754A Active JP7181185B2 (ja) 2016-09-16 2017-09-15 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2022125300A Pending JP2022140780A (ja) 2016-09-16 2022-08-05 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2024028183A Pending JP2024051102A (ja) 2016-09-16 2024-02-28 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022125300A Pending JP2022140780A (ja) 2016-09-16 2022-08-05 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
JP2024028183A Pending JP2024051102A (ja) 2016-09-16 2024-02-28 アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤

Country Status (9)

Country Link
US (1) US20190255000A1 (enExample)
EP (1) EP3512511A4 (enExample)
JP (3) JP7181185B2 (enExample)
KR (2) KR20240005122A (enExample)
CN (2) CN110167543A (enExample)
AU (3) AU2017326519B2 (enExample)
CA (1) CA3036989A1 (enExample)
MX (2) MX2019002976A (enExample)
WO (1) WO2018053358A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119233815A (zh) * 2022-05-20 2024-12-31 株式会社大赛璐 液态医药组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527538A (ja) 2002-03-19 2005-09-15 サイデックス・インコーポレイテッド 保存剤としてのスルホアルキルエーテルシクロデキストリンの使用
US20110015273A1 (en) 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
JP2013537891A (ja) 2010-09-13 2013-10-07 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
SI2277546T1 (sl) * 2009-07-23 2015-09-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stabilen pripravljen za uporabo injekcijski sestavek paracetamola
KR20160033795A (ko) * 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
CN102871994B (zh) * 2012-09-29 2015-07-29 中国科学院大连化学物理研究所 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
BR102014005885B1 (pt) * 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
SMT202100404T1 (it) * 2016-02-04 2021-09-14 Czap Research And Development Llc Veicoli di complessi di inclusione di ciclodestrine stratificati e rilascio controllato

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527538A (ja) 2002-03-19 2005-09-15 サイデックス・インコーポレイテッド 保存剤としてのスルホアルキルエーテルシクロデキストリンの使用
US20110015273A1 (en) 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
JP2013537891A (ja) 2010-09-13 2013-10-07 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム

Also Published As

Publication number Publication date
WO2018053358A1 (en) 2018-03-22
EP3512511A1 (en) 2019-07-24
US20190255000A1 (en) 2019-08-22
KR20190065296A (ko) 2019-06-11
CN110167543A (zh) 2019-08-23
JP2024051102A (ja) 2024-04-10
MX2019002976A (es) 2019-07-10
AU2025204233A1 (en) 2025-06-26
JP2022140780A (ja) 2022-09-27
EP3512511A4 (en) 2020-05-20
JP2019532927A (ja) 2019-11-14
MX2023003761A (es) 2023-04-26
AU2023203660A1 (en) 2023-07-06
CN116869983A (zh) 2023-10-13
AU2017326519B2 (en) 2023-03-16
RU2019107764A3 (enExample) 2021-01-15
RU2019107764A (ru) 2020-10-16
CA3036989A1 (en) 2018-03-22
KR20240005122A (ko) 2024-01-11
AU2017326519A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
AU2003234285B2 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20050085446A1 (en) Fluoroquinolone formulations and methods of making and using the same
JP2006518769A (ja) 安定な眼科用組成物
BRPI0921705B1 (pt) composição farmacêutica antimicrobiana e seu uso
AU2025204233A1 (en) Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
KR101156325B1 (ko) 방사선 보호 α,β 불포화 아릴설폰 제형
JP7597778B2 (ja) シクロデキストリン及びブスルファンを含有する組成物
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
CN116490211A (zh) 眼用组合物
RU2772384C9 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2772384C2 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2787621C2 (ru) Композиция, содержащая циклодекстрин и бусульфан
US20250186342A1 (en) Antiemetic combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220805

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220926

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221117

R150 Certificate of patent or registration of utility model

Ref document number: 7181185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250